Lannett Expands Strategic Relationship To Include Biosimilar Fast-Acting Insulin
- Tuesday, February 9, 2021, 7:14
- PR Newswire
- Add a comment
PHILADELPHIA, Feb. 9, 2021 /PRNewswire/ — Lannett Company, Inc. (NYSE: LCI) today announced that it has added a new co-development agreement for biosimilar insulin aspart with its strategic alliance partners within the HEC Group of companies (HEC). Insulin aspart, a short-acting…
About the Author
admin has written 20663 stories on this site.